Skip to Content

Mirtevuximab Soravtansine (Elahere)

Treatment Given by Infusion

Generic : Mirtevuximab Soravtansine (MEER-veh-TUK-sih-mab SOH-rav-TAN-seen)
Brand : Elahere (el-ah-HEER)
Download In :
Download 0.29MB
Last Update : June 19, 2023

About this Treatment

This regimen is most commonly used for the treatment of epithelial ovarian, fallopian tube, or primary peritoneal cancer but may be used for other diagnoses.

Disclaimer: Oral Chemotherapy Education (OCE) and Intravenous Cancer Treatment Education (IVE) documents are transitioning to Patient Education Sheets (PES) for consistency and ease of use. Accuracy will be maintained, but updates in formatting and terminology should be expected during this transition. This treatment sheet is under review for PES format.

What are Patient Education Sheets (PES)?

A Patient Education Sheet (PES) is a practical tool created with the unique needs of patients with cancer in mind. Each sheet translates complex treatment information into clear, patient-friendly language. They provide easy-to-follow medication schedules and guidance on managing potential side effects, helping patients and their caregivers feel informed and supported.

These resources are pulled directly by healthcare providers, who can download and print them for distribution during patient visits. This ensures that patients and caregivers leave the clinic with a reliable, easy-to-understand reference tailored to their treatment.

In addition to the standard content, PES documents are also editable in designated sections. Providers can add personalized details such as counseling notes, local resources, or contact information, making each sheet specific to the patient’s care journey.